NCT00932737 - (Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis | Biotech Hunter

Enrollment

197

Participants

Timeline

Start Date

June 9, 2009

Primary Completion Date

February 8, 2010

Study Completion Date

February 8, 2010

Conditions

Abdominal Pain

Interventions

DRUG

Placebo

1-5 tablets per episode

DRUG

HBB 20 mg

Active drug, one to five tablets per episode

Trial Locations (19)

202.839.01014 Boehringer Ingelheim Investigational Site, Westlake Village

202.839.01003 Boehringer Ingelheim Investigational Site, Hollywood

202.839.01001 Boehringer Ingelheim Investigational Site, Jupiter

202.839.01002 Boehringer Ingelheim Investigational Site, Jupiter

202.839.01017 Boehringer Ingelheim Investigational Site, Rockford

202.839.01005 Boehringer Ingelheim Investigational Site, Indianapolis

202.839.01019 Boehringer Ingelheim Investigational Site, Chevy Chase

202.839.01009 Boehringer Ingelheim Investigational Site, Boston

202.839.01004 Boehringer Ingelheim Investigational Site, Lebanon

202.839.01011 Boehringer Ingelheim Investigational Site, Toms River

202.839.01008 Boehringer Ingelheim Investigational Site, Lake Success

202.839.01015 Boehringer Ingelheim Investigational Site, Cleveland

202.839.01021 Boehringer Ingelheim Investigational Site, Norman

202.839.01010 Boehringer Ingelheim Investigational Site, Oklahoma City

202.839.01013 Boehringer Ingelheim Investigational Site, Philadelphia

202.839.01006 Boehringer Ingelheim Investigational Site, San Antonio

202.839.01012 Boehringer Ingelheim Investigational Site, San Antonio

202.839.01007 Boehringer Ingelheim Investigational Site, Virginia Beach

202.839.01020 Boehringer Ingelheim Investigational Site, Milwaukee